文献速递流行病学与生物统计医学人工智能与信息学基础与转化研究

双相障碍循证干预:跨阶段与年龄组的活伞状综述及U-REACH项目

Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project.
PubMed 文献 · BMJ · 2026-08-11

该活伞状综述系统评估了双相障碍不同年龄与心境阶段的治疗证据确定性,纳入77项系统综述(含21项网络Meta分析和56项配对Meta分析),覆盖116种独特治疗和133个结局,并开发了开放获取的EBI-BD网络平台以辅助共享决策。

要点

  • 双相抑郁成人有效干预包括卡利拉嗪、丙戊酸盐、氟西汀、氯胺酮(增效)、拉莫三嗪、鲁拉西酮、奥氮平、喹硫平等。
  • 双相躁狂成人有效干预包括阿立哌唑、阿塞那平、卡马西平、卡利拉嗪、丙戊酸盐、氟哌啶醇、锂盐、奥氮平、喹硫平等。
  • 维持期成人有效干预包括阿立哌唑(含长效针剂)、阿塞那平、丙戊酸盐、锂盐、奥氮平、团体心理教育(增效)、喹硫平、利培酮长效针剂。

核心结论

  • EBI-BD工具可帮助临床医生为双相障碍做出循证、个体化的治疗决策。
  • 该资源可为临床指南提供信息,并为持续改善双相障碍照护奠定基础。

研究设计与样本

  • 活伞状综述、评价、分析与传播中心(U-REACH)项目。
  • 检索PubMed、PsycInfo和Cochrane图书馆数据库,从建库至2024年11月19日。
  • 纳入77项系统综述(21项网络Meta分析和56项配对Meta分析),涵盖116种独特治疗和5种对照干预。

主要发现

  • 共产生2510项Meta分析,GRADE证据确定性评级为高(n=236)、中(n=827)、低(n=986)和极低(n=461)。
  • 双相抑郁成人有效干预包括卡利拉嗪、双丙戊酸或丙戊酸盐、氟西汀、氯胺酮(增效)、拉莫三嗪、鲁美哌隆、鲁拉西酮、奥氮平、奥氮平联合氟西汀和喹硫平。
  • 双相抑郁儿童青少年有效干预为鲁拉西酮和奥氮平联合氟西汀。
  • 双相躁狂成人有效干预包括阿立哌唑、阿塞那平、卡马西平、卡利拉嗪、双丙戊酸或丙戊酸盐、氟哌啶醇、锂盐、奥氮平、帕利哌酮、喹硫平(亦增效)、利培酮(亦增效)、他莫昔芬和齐拉西酮。
  • 双相躁狂儿童青少年有效干预包括阿立哌唑、阿塞那平、奥氮平、喹硫平和利培酮。

关键数值与推荐

  • 维持期成人有效干预包括阿立哌唑(亦长效针剂)、阿塞那平、双丙戊酸或丙戊酸盐、锂盐、奥氮平、团体心理教育(增效)、喹硫平和利培酮长效针剂。
  • 跨阶段成人有效干预包括阿立哌唑(亦增效和长效针剂)、阿塞那平、卡利拉嗪、认知行为治疗(增效)、双丙戊酸或丙戊酸盐、拉莫三嗪、锂盐、奥氮平(亦增效)、帕利哌酮、喹硫平(亦增效)和利培酮(亦增效和长效针剂)。
  • EBI-BD平台(https://ebibd-database.org)免费提供全部结果,包括偏好工具(12种干预和17种安全性结局)。

临床怎么用

  • 临床医生可利用EBI-BD平台查询双相障碍不同阶段和年龄组的循证干预及其证据确定性。
  • 该工具支持基于偏好的共享决策,帮助实现个体化治疗。

局限性

  • 本活系统综述可能在未来两年内根据新证据更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To systematically evaluate the certainty of evidence for treatment strategies across age groups and mood phases in bipolar disorder, and develop an open access web platform to facilitate shared decision making. DESIGN: Living umbrella review, evaluation, analysis, and communication hub (U-REACH) project. DATA SOURCES: PubMed, PsycInfo, and Cochrane library databases, from inception to 19 November 2024. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews with network or pairwise meta-analyses of randomised controlled trials of pharmacological, nutraceutical, psychosocial, brain stimulation, or circadian rhythm based treatments, administered as monotherapy (without concurrent interventions), augmentation treatment (interventions added to an ongoing treatment regimen), or combination treatment (simultaneous initiation of two different interventions), examining any age group, bipolar disorder phase (ie, acute bipolar depression, mania or mixed episodes, or maintenance), treatment, control, or outcome. RESULTS: 77 studies met the inclusion criteria (21 network meta-analyses and 56 pairwise meta-analyses), including 116 unique pharmacological (n=74), brain stimulation (n=18), nutraceutical (n=13), psychosocial (n=8), and circadian rhythm based (n=3) treatments as monotherapy, augmentation, or combination therapy, along with five control interventions. These studies covered 133 unique outcomes (45 efficacy outcomes and 88 safety outcomes) resulting in 2510 meta-analyses with Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) ratings of the certainty of the evidence as high (n=236), moderate (n=827), low (n=986), and very low (n=461). A communication hub, the Evidence Based Interventions for Bipolar Disorder (EBI-BD) platform, was developed and the full results are freely available (https://ebibd-database.org), including the preference based tool (12 interventions and 17 safety outcomes). Interventions effective across outcomes varied by phases. For bipolar depression, effective interventions in adults were cariprazine, divalproex or valproate, fluoxetine, ketamine (augmentation), lamotrigine, lumateperone, lurasidone, olanzapine, olanzapine with fluoxetine, and quetiapine, whereas effective interventions in children and adolescents were lurasidone and olanzapine with fluoxetine. For mania episodes, effective interventions in adults were aripiprazole, asenapine, carbamazepine, cariprazine, divalproex or valproate, haloperidol, lithium, olanzapine, paliperidone, quetiapine (also augmentation), risperidone (also as augmentation), tamoxifen, and ziprasidone, whereas effective interventions in children and adolescents were aripiprazole, asenapine, olanzapine, quetiapine, and risperidone. For maintenance, interventions effective across outcomes in adults were aripiprazole (also the long acting injectable formulation), asenapine, divalproex or valproate, lithium, olanzapine, group psychoeducation (augmentation), quetiapine, and risperidone long acting injectable formulation. Interventions effective across phases were aripiprazole (also as augmentation and as a long acting injectable formulation), asenapine, cariprazine, cognitive behavioural therapy (augmentation), divalproex or valproate, lamotrigine, lithium, olanzapine (also as augmentation), paliperidone, quetiapine (also as augmentation), and risperidone (also as augmentation and the long acting injectable formulation) (adults). Treatment effects by neuroscience based nomenclature classes are also reported. CONCLUSIONS: The EBI-BD tool can help clinicians make evidence based, personalised treatment decisions for bipolar disorder. This resource can inform clinical guidelines and provides a foundation for continuously improving bipolar disorder care as new evidence emerges. TRIAL REGISTRATION: Open Science Framework https://osf.io/pjmvn/ READERS' NOTE: This is a living systematic review and may be updated in the next two years if additional evidence emerges.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. De Prisco M, Oliva V, Miola A, et al. Evidence based interventions for bipolar disorder across phases and age groups: living umbrella review, evaluation, analysis, and communication hub (U-REACH) project. BMJ. 2026. PMID: 42580772. doi:10.1136/bmj-2026-100216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。